Extended Data Fig. 3: Reduced infectious virus in the lungs of antibody-treated mice.
From: In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
a, b, Eight-to-ten-week-old female and male K18-hACE2 transgenic mice received 40 μg (about 2 mg kg−1) of the indicated mAb treatment by intraperitoneal injection one day before intranasal inoculation with 103 FFU of the indicated SARS-CoV-2 strain. Tissues were collected at six days after infection. c–f, Six-to-seven-week-old female and male immunocompetent 129S2 mice received 40 μg (about 2 mg kg−1) of the indicated mAb treatment by intraperitoneal injection one day before intranasal inoculation with 103 FFU of WA1/2020 N501Y/D614G, Wash-B.1.351 or Wash-B.1.1.28 and 105 FFU of B.1.1.7. Tissues were collected at three days after infection. g, h, Eight-to-ten-week-old female and male K18-hACE2 transgenic mice were administered 103 FFU of the indicated SARS-CoV-2 strain by intranasal inoculation. One day later, mice received 200 μg (about 10 mg kg−1) of the indicated mAb treatment by intraperitoneal injection. Tissues were collected at six days after infection. For all panels, infectious virus in lung homogenates was determined by plaque assay using Vero-hACE2-TMPRSS2 cells (line indicates median; in order from left to right n = 5, 5, 5, 6, 6 and 6 (a); n = 6, 6, 6, 6, 6 and 6 (b–h) mice per group, one-way ANOVA with Dunnett’s test with comparison to control mAb: ns, not significant, ****P < 0.0001; **P = 0.0012, ***P = 0.0003 (c); **P = 0.0048, ***P = 0.0005 (e); **P = 0.0031, 0.0019 and 0.0020 (f, from left to right)). Dotted lines indicate the limit of detection of the assay.
